EDAP and Telix Collaborate on Prostate Cancer Treatment Innovation
EDAP TMS S.A. has announced a collaboration with Telix Pharmaceuticals to advance the integration of robotic High Intensity Focused Ultrasound (HIFU) and PSMA PET imaging in prostate cancer treatment. The partnership aims to improve treatment planning, delivery, and monitoring, enhancing patient outcomes in both primary and salvage treatment settings. Educational initiatives and clinical studies are also part of the collaboration, which does not impose any financial obligations on either party.
, May 14, 2026 (GLOBE NEWSWIRE) — AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP’s Focal One Robotic HIFU and Telix’s PSMA PET imaging products in the management of prostate cancer.